Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · market

Curium To Buy Radiopharmaceutical Company Lantheus In Up To $8Bn Deal

4 August 2026 · By · Wire by Fusion42

Published

4 August 2026

Topic

market

◆ Sectors

Health

◆ Geography

United States

◆ Source

Read at insights.citeline.com →

◆ Verified

Fusion42 · 4 August 2026 · Fusion42 review

Curium has agreed to acquire radiopharmaceutical company Lantheus in a deal valued at up to $8 billion, expanding Curium's footprint in the nuclear imaging and radiopharmaceutical market.

This Wire brief sits within Fusion42's coverage of Health, and 2 sources have reported it.

◆ ◆ The Wire takeaway

Your radiopharma market is consolidating fast, and this deal creates a larger competitor with broader assets. Act now to pitch adoption or reposition before this combined entity dominates key imaging products.

◆ Coverage

2 sources · 4 Aug 2026

◆ Related on Wire

◆ Topics

Healthcuriumlantheusradiopharmaceuticalsm-anuclear-imaging